Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 561 to 570 of 2591 total matches.

Ashwagandha Supplements

   
The Medical Letter on Drugs and Therapeutics • Mar 08, 2021  (Issue 1619)
, and various cancers.1 AVAILABILITY — Ashwagandha is available commercially in tablets, capsules, liquid ...
Ashwagandha is an herb extracted from the roots of an evergreen shrub (Withania somnifera) found in India that has been used as a "tonic" for centuries. No specific constituent has been identified as an active ingredient. Herbal supplements containing ashwagandha, which is also known as winter cherry and Indian ginseng, are widely promoted now in the US for treatment of pain, anxiety, stress, fatigue, sleep disturbances, cognitive decline, diabetes, arthritis, male infertility, and various cancers.
Med Lett Drugs Ther. 2021 Mar 8;63(1619):39-40 |  Show IntroductionHide Introduction

Vericiguat (Verquvo) for Heart Failure

   
The Medical Letter on Drugs and Therapeutics • Mar 08, 2021  (Issue 1619)
thromboembolic pulmonary hypertension, was the first.1 Pronunciation Key Vericiguat: ver” i sig’ ue at Verquvo ...
The FDA has approved vericiguat (Verquvo – Merck), an oral soluble guanylate cyclase (sGC) stimulator, to reduce the risk of hospitalization for heart failure and cardiovascular (CV) death following a worsening heart failure event (hospitalization for heart failure or treatment with IV diuretics as an outpatient) in patients with symptomatic chronic heart failure and left ventricular ejection fraction (LVEF) <45%. Vericiguat is the second sGC stimulator to be marketed in the US. Riociguat (Adempas), which is FDA-approved for treatment of pulmonary arterial hypertension...
Med Lett Drugs Ther. 2021 Mar 8;63(1619):36-7 |  Show IntroductionHide Introduction

Drugs for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Feb 22, 2021  (Issue 1618)
are thought to be caused by degeneration of other neurotransmitter systems.1,2 No disease-modifying drugs ...
The motor symptoms of Parkinson's disease (PD) are caused primarily by degeneration of dopaminergic neurons in the substantia nigra. The nonmotor symptoms of the disease are thought to be caused by degeneration of other neurotransmitter systems. No disease-modifying drugs are available for treatment of PD.
Med Lett Drugs Ther. 2021 Feb 22;63(1618):25-32 |  Show IntroductionHide Introduction

Comparison Table: Drugs for Parkinson's Disease (online only)

   
The Medical Letter on Drugs and Therapeutics • Feb 22, 2021  (Issue 1618)
in blister packs; a new inhaler should be used with each new carton 84 mg inhaled 1-5x/day prn iFDA ...
View the Comparison Table: Drugs for Parkinson's Disease
Med Lett Drugs Ther. 2021 Feb 22;63(1618):e1-9 |  Show IntroductionHide Introduction

Twirla - A New Contraceptive Patch

   
The Medical Letter on Drugs and Therapeutics • Feb 08, 2021  (Issue 1617)
hormonal contraceptives. Unscheduled bleeding/spotting lasting ≥1 day occurred in 60.4% of women in cycle ...
The FDA has approved Twirla (Agile Therapeutics), a transdermal contraceptive patch containing the estrogen ethinyl estradiol and the progestin levonorgestrel, for use in women with a BMI <30 kg/m2. It is the second contraceptive patch to become available in the US; Xulane, a patch that delivers ethinyl estradiol and the progestin norelgestromin, has been available since 2014.
Med Lett Drugs Ther. 2021 Feb 8;63(1617):17-8 |  Show IntroductionHide Introduction

Pitolisant (Wakix) for Narcolepsy

   
The Medical Letter on Drugs and Therapeutics • Feb 08, 2021  (Issue 1617)
; it has not been compared to first-line treatments.1 A sodium oxybate oral solution (Xyrem) and a mixed-salt oxybate oral ...
The FDA has approved pitolisant (Wakix – Harmony), a histamine-3 (H3)-receptor antagonist/inverse agonist, for treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy. It is the first H3-receptor antagonist/inverse agonist to become available in the US and the first non-controlled substance to receive FDA approval for these indications. Pitolisant has been available in Europe since 2016.
Med Lett Drugs Ther. 2021 Feb 8;63(1617):19-21 |  Show IntroductionHide Introduction

Osilodrostat (Isturisa) for Cushing's Disease

   
The Medical Letter on Drugs and Therapeutics • Feb 08, 2021  (Issue 1617)
for coronary artery disease, stroke, venous thromboembolism, and serious infections.1 STANDARD TREATMENT ...
The FDA has approved osilodrostat (Isturisa – Recordati), a cortisol synthesis inhibitor, for oral treatment of adults with Cushing's disease when surgical resection of the pituitary adenoma is not an option or has not been curative. Osilodrostat is the first cortisol synthesis inhibitor to be approved in the US for this indication. Other oral steroidogenesis inhibitors such as ketoconazole and metyrapone have been used off-label for this indication for many years.
Med Lett Drugs Ther. 2021 Feb 8;63(1617):21-3 |  Show IntroductionHide Introduction

Avapritinib (Ayvakit) for GIST

   
The Medical Letter on Drugs and Therapeutics • Feb 08, 2021  (Issue 1617)
mutations.1 The PDGFRA D842V mutation is the most common exon 18 mutation. The oral tyrosine kinase ...
The FDA has approved the oral tyrosine kinase inhibitor avapritinib (Ayvakit – Blueprint Medicines) for treatment of unresectable or metastatic gastrointestinal stromal tumors (GISTs) harboring a platelet-derived growth factor receptor alpha (PDGFRA) D842V or other PDGFRA exon 18 mutation. Avapritinib is the first drug to be approved for this indication in the US.
Med Lett Drugs Ther. 2021 Feb 8;63(1617):23-4 |  Show IntroductionHide Introduction

Sacituzumab Govitecan (Trodelvy) for Metastatic Triple-Negative Breast Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Feb 08, 2021  (Issue 1617)
months), and an optimal sequence of treatment has not been established.1,2 Some patients with advanced ...
The FDA has approved sacituzumab govitecan-hziy (Trodelvy – Immunomedics), a trophoblast cell-surface antigen-2 (Trop-2)-directed antibody and topoisomerase inhibitor conjugate, for treatment of adults with metastatic triple-negative breast cancer who have received ≥2 prior therapies for metastatic disease. It is the first Trop-2-directed antibody-drug conjugate to become available in the US.
Med Lett Drugs Ther. 2021 Feb 8;63(1617):e24-5 |  Show IntroductionHide Introduction

Antibacterial Drugs for Community-Acquired Pneumonia

   
The Medical Letter on Drugs and Therapeutics • Jan 25, 2021  (Issue 1616)
Thoracic Society and the Infectious Diseases Society of America (ATS/IDSA) were updated in 2019.1 ...
Treatment of community-acquired pneumonia (CAP) is usually empiric, with selected antibiotic regimens directed against some of the most common causative pathogens. Recommended empiric regimens are listed in Table 2; recommended antibiotic dosages for treatment of CAP are listed in Tables 3 and 4. Joint guidelines for treatment of CAP by the American Thoracic Society and the Infectious Diseases Society of America (ATS/IDSA) were updated in 2019.
Med Lett Drugs Ther. 2021 Jan 25;63(1616):10-5 |  Show IntroductionHide Introduction